| Title: |
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 |
| Authors: |
Bakouny, Ziad; Labaki, Chris; Grover, Punita; Awosika, Joy; Gulati, Shuchi; Hsu, Chih-Yuan; Alimohamed, Saif I; Bashir, Babar; Berg, Stephanie; Bilen, Mehmet A; Bowles, Daniel; Castellano, Cecilia; Desai, Aakash; Elkrief, Arielle; Eton, Omar E; Fecher, Leslie A; Flora, Daniel; Galsky, Matthew D; Gatti-Mays, Margaret E; Gesenhues, Alicia; Glover, Michael J; Gopalakrishnan, Dharmesh; Gupta, Shilpa; Halfdanarson, Thorvardur R; Hayes-Lattin, Brandon; Hendawi, Mohamed; Hsu, Emily; Hwang, Clara; Jandarov, Roman; Jani, Chinmay; Johnson, Douglas B; Joshi, Monika; Khan, Hina; Khan, Shaheer A; Knox, Natalie; Koshkin, Vadim S; Kulkarni, Amit A; Kwon, Daniel H; Matar, Sara; McKay, Rana R; Mishra, Sanjay; Moria, Feras A; Nizam, Amanda; Nock, Nora L; Nonato, Taylor K; Panasci, Justin; Pomerantz, Lauren; Portuguese, Andrew J; Provenzano, Destie; Puc, Matthew; Rao, Yuan J; Rhodes, Terence D; Riely, Gregory J; Ripp, Jacob J; Rivera, Andrea V; Ruiz-Garcia, Erika; Schmidt, Andrew L; Schoenfeld, Adam J; Schwartz, Gary K; Shah, Sumit A; Shaya, Justin; Subbiah, Suki; Tachiki, Lisa M; Tucker, Matthew D; Valdez-Reyes, Melissa; Weissmann, Lisa B; Wotman, Michael T; Wulff-Burchfield, Elizabeth M; Xie, Zhuoer; Yang, Yuanchu James; Thompson, Michael A; Shah, Dimpy P; Warner, Jeremy L; Shyr, Yu; Choueiri, Toni K; Wise-Draper, Trisha M |
| Source: |
Hematology/Oncology Articles |
| Publisher Information: |
Henry Ford Health Scholarly Commons |
| Publication Year: |
2022 |
| Collection: |
Henry Ford Health System Scholarly Commons |
| Description: |
IMPORTANCE: Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation. OBJECTIVE: To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings. EXPOSURES: Immunosuppression due to therapy; systemic anticancer therapy (IO or non-IO). MAIN OUTCOMES AND MEASURES: The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm. RESULTS: The median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine ... |
| Document Type: |
text |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
https://scholarlycommons.henryford.com/hematologyoncology_articles/263; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:36326731 |
| Availability: |
https://scholarlycommons.henryford.com/hematologyoncology_articles/263; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:36326731 |
| Accession Number: |
edsbas.712AFF3C |
| Database: |
BASE |